CI

At a glance

ClinicalIndex Comparison Record
Phase 3Recruiting· 500 target
Drug / intervention
Bleomycin (active name: Bleomycin Sulfate) +4 moredrug
Likely dose
Etoposide 100 mg/m2from record
Key inclusion· 7
  • Age 11-50 years at randomization
  • Histologically or cytologically confirmed germ cell tumor (non-seminoma or seminoma)
  • Exceptionally raised tumor markers can substitute for histologic confirmation in urgent cases
  • Primary tumor location: testis, ovary, retroperitoneum, or mediastinum
Key exclusion· 8
  • Other active primary malignancy (exceptions: adequately treated non-melanomatous skin cancer, germ cell tumor, or malignancy treated ≥5 years ago with no recurrence)
  • Prior chemotherapy or radiotherapy, with specific exceptions
  • Significant cardiac disease preventing IV fluid hydration for cisplatin
  • Significant respiratory disease contraindicating bleomycin use

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02582697
NCT02582697Phase 3RecruitingHigh MomentumUpdated 12mo ago
Long Recruiting

Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

University of Sydney·interventional·Posted Oct 21, 2015·Updated Jun 15, 2025

In Brief

A Phase 3 clinical trial evaluating Bleomycin (active name: Bleomycin Sulfate), Etoposide, and 3 other interventions for Germ Cell Tumor. Currently recruiting, targeting 500 participants across 28 sites in 3 countries.

Signals

Enrolling ahead of pace

Detailed Summary

The purpose of this study is to determine whether accelerated BEP chemotherapy is more effective than standard BEP chemotherapy in males with intermediate and poor-risk metastatic germ cell tumours.

Study Details

Timeline

Phase 3Recruiting
20142015201620172018201920202021202220232024202520262027202820292030
First PostedOct 21, 2015
Enrollment StartFeb 1, 2014
Primary CompletionDec 31, 2029
TodayJul 2, 2026
Enrollment to primary: 15.9 yearsPosted 10.7 years agoPrimary completion in 3.5 years

Interventions

Bleomycin (active name: Bleomycin Sulfate)drug

Standard Arm: Bleomycin 30,000 international units IV weekly for 3 doses (eg. days 1, 8 and 15 or days 2, 9 and 16 of a 21-day cycle) for 4 cycles. Accelerated Arm: Bleomycin 30,000 international units IV weekly for 2 doses (eg. days 1 and 8 or days 2 and 9 of a 14-day cycle) for 4 cycles. Followed by Bleomycin 30,000 international units IV weekly for 4 doses.

Etoposidedrug

Standard Arm: Etoposide 100 mg/m2 IV on days 1, 2, 3, 4, 5 of a 21-day cycle for 4 cycles. Accelerated Arm: 100 mg/m2 IV on days 1, 2, 3, 4, 5 of a 14-day cycle for 4 cycles.

Cisplatindrug

Standard Arm: Cisplatin 20 mg/m2 IV on days 1, 2, 3, 4, 5 of a 21-day cycle for 4 cycles. Accelerated Arm: Cisplatin 20 mg/m2 IV on days 1, 2, 3, 4, 5 of a 14-day cycle for 4 cycles.

Pegylated G-CSF (Pegfilgrastim)drug

Standard Arm: 6 mg SCI on day 6 of a 21-day cycle for 4 cycles. Accelerated Arm: 6 mg SCI on day 6 of a 14-day cycle for 4 cycles.

Filgrastimdrug

Standard Arm: 10 mcg/kg/day on day6, until post-nadir absolute neutrophil count ≥ 1.0 x 10\^9/L, of a 21-day cycle for 4 cycles. Accelerated Arm: 10 mcg/kg/day on day 6, until post-nadir absolute neutrophil count ≥ 1.0 x 10\^9/L, of a 14-day cycle for 4 cycles.